An inhibitor of triggering receptor expressed on myeloid cells 1 (TREM-1) for use in the treatment of coronavirus disease 2019 (COVID-19) in a subject in need thereof, in particular in a subject suffering from a severe form and/or a complication of COVID-19. Also, the use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from COVID-19 susceptible to respond to a TREM-1 inhibitor and in a method for monitoring the effectiveness of TREM-1 inhibitor administered to a subject suffering from COVID-19.

The invention relates to using cell free nucleosome levels to identify patients at risk of developing a NETosis associated adverse reaction to the infection. The methods are used to monitor the progress of a disease and assigning a risk of an adverse outcome in a patient suffering from an infection.

The present disclosure relates to compositions comprising a non-viable fecal bacterial preparation for treating various gastrointestinal-related conditions and disorders. The present disclosure also relates to stool-based compositions comprising adjuvants to facilitate the efficacy of immunomodulators such as vaccines and immunotherapies.

The present disclosure relates to a method for determining the potency of an antigen sample such as a vaccine antigen sample. The present disclosure is also related to a method for monitoring the potency of a vaccine antigen during the production process including purifying, inactivating and formulating the vaccine antigen and to a method for producing a virus vaccine. Further, the present disclosure relates to vaccines obtainable by the methods disclosed. In certain embodiments of the present invention the antigen sample is a zika virus antigen sample.

A bioassay system includes at least one conductive excitation coil, the at least one conductive excitation coil configured to generate an alternating magnetic field including a first frequency and a second frequency. The bioassay system further includes a sample mount configured to position a sample within the at least one conductive excitation coil, and at least one sensing conductive coil configured to determine a magnetic response of a sample positioned within the sample mount to the alternating magnetic field.

The disclosure provides compositions and methods for detecting coronaviruses, in particular SARS-CoV-2, in biological samples. The disclosure also provides compositions and methods for simultaneously detecting coronaviruses and influenzaviruses in biological samples.

Human ACE2 variants are provided including methods of use thereof. The ACE2 receptor variants may be used for diagnosis and treatment of COVID-19.

Described are point of care tests to detect circulating neutralizing antibodies against SARS-CoV-2 or another virus in a sample obtained from patients. The tests comprise lateral flow test strips and methods of use thereof.

The present disclosure provides a digital microfluidic (DMF) cartridge for performing a self-test for a target analyte, including a DMF cartridge comprising a bottom substrate and a top substrate separated by a droplet operations gap, wherein the bottom substrate comprises a plurality of droplet operations electrodes configured for performing droplet operations on a liquid droplet in the droplet operations gap; one or more reaction chambers or reaction zones on the bottom substrate that are supplied by an arrangement of the droplet operations electrodes, wherein each reaction chamber or reaction zone comprises at least one detection spot and is configured for performing a plasmonic particle-assisted ELISA (pELISA) for detection and quantification of a target analyte in a sample droplet. The device may include downloadable software for a self-test and be operable using a smart device.

Provided herein are high-throughput, population-wide serotyping and antibody profiling assays. Disclosed variants of a Digital Serotyping assay employ next generation sequencing to measure the “serotyping profile” of barcoded subject serum antibodies tested against a range of DNA-tagged pathogen-derived antigens. The disclosed assay setup enables multiplexing in both the sample and antigen dimensions, generating a large multi-dimensional serotyping data set for more comprehensive serotyping profiling of large populations across a large number of antigens and possible pathogens. Moreover, the ability to easily scale and multiplex the number of peptide epitopes allows rapid updating of the assay content to monitor the ever-changing spectrum of pathogens. Additional applications of this technology include cancer immunology and autoimmune conditions (e.g., neoantigen or autoimmune profiling), screening for toxins, antibody therapeutics development, biosecurity, and veterinary medicine.